Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

Summary

This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.

Timeline

Start

2021-10-06

Primary completion

2022-10-27

Completion

2022-11-27

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive” addextherapeutics.com ↗

Drugs

Indications